B7-H3-targeted CAR-Vδ1T Cells (Miltenyi Biotec/Lentigen Technology)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameB7-H3-targeted CAR-Vδ1T Cells (Miltenyi Biotec/Lentigen Technology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMiltenyi Biotec BV & Co KGLentigen Technology Inc
China Registration ClassN/A

Develop Information

Active CompaniesLentigen Technology Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A